Adjuvant pembrolizumab for postnephrectomy renal cell carcinoma (RCC): Expanded efficacy analyses from KEYNOTE-564.
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Toni K. Choueiri, Piotr Tomczak, Se Hoon Park, Balaji Venugopal, Tom Ferguson, Stefan N. Symeonides, Jaroslav Hajek, Yen-Hwa Chang, Jae-Lyun Lee, Naveed Sarwar, Antoine Thiery-Vuillemin, Marine Gross-Goupil, Mauricio Mahave, Naomi B. Haas, Piotr Sawrycki, Howard Gurney, Lei Xu, Kentaro Imai, Jackie Rogerio, Thomas Powles
Institutions: Harvard University, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, Poznan University of Medical Sciences, Samsung Medical Center, Sungkyunkwan University, Beatson West of Scotland Cancer Centre, University of Glasgow, Fiona Stanley Hospital, Edinburgh Cancer Research, University of Edinburgh, University Hospital Ostrava, Taipei Veterans General Hospital, Asan Medical Center, University of Ulsan, Imperial College Healthcare NHS Trust, Centre Hospitalier Universitaire de Besançon, Hôpital Saint-André, Fundación Arturo López Pérez, University of Pennsylvania Health System, Abramson Cancer Center, Provincial Polyclinical Hospital in Toruń, Macquarie University, Merck & Co., Inc., Rahway, NJ, USA (United States), Queen Mary University of London, Barts Health NHS Trust, The Royal Free Hospital, Barts Cancer Institute
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4286297235